The effect of alpha-cyclodextrin on post-prandial glucose excursions, a systematic meta analysis

Alpha-cyclodextrin and Blood Glucose

KNUT M. WITTKOWSKI[1*]

[1] ASDERA LLC, New York, NY, United States

* Correspondence: Knut M. Wittkowski, ASDERA LLC, New York, NY 10028, USA
knut@asdera.com (KMW)

Alpha-cyclodextrin (αCD) is a bacterial product that is widely used as a food ingredient. In the EU, αCD is regulated as a "dietary fiber" with an authorized health claim "for contributing to the reduction of post-prandial glycemic responses". In the US, αCD is GRAS (generally recognized as save), but the FDA recently rejected the inclusion of αCD in the list of "dietary fibers", because "the strength of the scientific evidence does not support a finding of a beneficial effect of αCD on postprandial blood glucose …". The meta-analysis presented here provides a review of studies conducted on the effect of different amounts of αCD on the rise of blood glucose levels after consumption of ~50 g of starch.

INTRODUCTION

As soluble fibers, cyclodextrins (CDs) comprise several glucose molecules. In contrast to many other fibers, however, these fibers form not a linear structure, but a ring, which make them inaccessible to most organisms. Only some bacteria, which have the enzymes to open these rings can digest the glucose units.

These rings have an interesting physicochemical property: they are hydrophilic on the outside, making the CDs water-soluble, and lipophilic on the insight, allowing them to carry lipids through water (gut, serum), either to deliver drugs or to filter out ("deplete") serum lipids.

Alpha-, beta-, and gamma-CDs (αCDs, βCDs, γCDs) are soluble fibers comprising rings of six, seven, and eight sugars, respectively, and, thus, can fit lipids of different size. αCDs bind preferentially saturated and trans fatty acids (FAs),(Plank David 2006; Gentilcore 2011; Jen 2013; Bär 2020; Bessell 2020) the larger βCDs can also fit steroids and sterols, while γCDs are large enough to carry various other molecules. Their high specificity for "bad" FAs makes αCDs particularly interesting as dietary fibers.

In several clinical trials, αCDs have also shown to reduce the increase of blood sugar after a carbohydrate-rich meal. This meta-analysis aims to integrate the information from these clinical trials.

METHODS

When only *P*-values, but no effect estimates or individual data are available, meta-analyses can be conducted by aggregating information from *P*-values. Fisher's combined probability test (FCPT) (Fisher 1948) is the most asymptotically optimal method in terms of Bahadur efficiency (Littell 1973). If results are concurrent (pointing into the same direction), the combined *P*-value can be calculated from:

$$2\ \Sigma_{i=1\ldots k}\ -\ln(P_i) \sim \chi^2_{2k}$$

For instance, the requirement of two studies ($k = 2$) significant at the conventional $P_i = 0.05$ level for approval of a drug translates to a combined $P(4\times2.996 = 11.98 > \chi^2_4) = .0175$. One important consequence is that including an additional concurrent test with $P < 0.37$ (asymptotically) improves overall significance (Elston 1991). Hence, a third study with $P = 0.05 \ldots 0.37$ improves the overall significance of two studies conventionally significant at the 0.05 level each. If one of the two studies were significant at a level of e.g., $P < .01$, the third study might have to point into the opposite direction to void the significance of the two studies.

When *P*-values are reported as categorial ($P > 0.05$), a meta-analysis can also be guided by the inspection of the figures in the source publications. To facilitate comparisons, the figures given below have been scaled and cropped, and elements have been resized or removed (like indicators of significance of comparisons not being considered), while some information have been added from the text. No information was removed, except values beyond 180 min (2 h) in two studies (Gentilcore 2011; Lytle 2018).

com

MATERIALS,

Search

In September 2022, three publicly available data bases (clinicaltrials.gov, PubMed, and Google Scholar) were searched for clinical trials regarding the efficacy of αCD in reducing postprandial glucose excursions after a meal rich in carbohydrates.

This systematic review and included clinical studies of dietary interventions that

- enrolled, regardless of their age and background, who were generally healthy.
- were randomized or non-randomize
- included carbohydrates in the diet
- included alpha-cyclodextrin as an intervention
- included (post-prandial) blood glucose profiles as an outcome.

Many publications included also Insulin and triglyceride profiles, but a search for “insulin” or “triglyceride” did not yield additional results.

Data Sources, Literature Search Criteria, and Records Retrieved

Data sources used where ClinicalTrials.gov, MedLine (PubMed), Google Scholar as well as the publications identified as relevant in these sources or referencing the sources (»).

- ClinicalTrials.gov

  Study type: Interventional Studies (Clinical Trials)

  Intervention/Treatment: Alpha-Cyclodextrin

  Outcome Measure: Glucose

  Other term: carbohydrate -- removed to get results)

  - **Lytle/Jensen (2018)** NCT02999620 / NCT03002168
  - Amar (2016) NCT01131299 – 6 g/d, 12–14 wk, no single-day profiles taken
  - Soklavini (2022) NCT05393843 – terminated because of poor compliance (COVID)
- MedLine: Clinical Trial, “carbohydrate alpha-cyclodextrin glucose”
  - **Buckley (2006)**
  - Comerford (2011) – glucose profiles not an outcome

    » Grunberger (2007) – serum glucose measured in diabetic patients not reported
  - **Gentilcore (2011)**
  - **Jarosz (2013)**
  - Amar (2016) – duplicate
  - Bessell 2020 – glucose profiles not an outcome
- Google scholar: carbohydrate alpha-cyclodextrin glucose post-prandial clinical
  - Buckley (2006) – duplicate
  - Gentilcore (2011) – duplicate
  - Jarosz/Fletcher (2013) – duplicate
  - Amar (2016) – duplicate
  - Jain (2016) – glucose profiles are not an outcome.
  - **Bär/Diamantis/Schmidt (2020/12/04)** – in PubMed, but not as a “clinical trial” some results also described in **US 2004/0161526 A1** (Wacker, abandoned) (Schmid 2004a)

    » Sugahara (2016) – not in PubMed
  - Lytle/Jensen (2018) – duplicate
  - **Binou (2022) –** not in PubMed



Figure 1: PRISM 2020 Flow Diagram

The list of trials includes the three trials relied on by the EFSA in its 2012 decision on the health claim related to alpha-cyclodextrin and post-prandial glycemic responses (EFSA Panel on Dietary Products 2012) and the additional two studies included by the by the FDA (Kavanaugh 2022) in its 2022 assessment of αCD as a dietary fiber. Three additional publications were identified. One had glucose profiles only as a secondary outcome (Lytle 2018), the other two were published only after the FDA had made its decision; one is included (Binou 2022a; b), the other (a combination treatment with 5 g aCD per meal, 45% calories from carbohydrates) was terminated because of poor compliance during COVID (Soldavini 2022).

The EFSA based it's 2012 scientific opinion on the following three clinical trials:

- Buckley et al. (2006)(Buckley 2006):10 healthy adults age 24 ± 4 yr consumed boiled rice (50 g digestible carbohydrates) with 0, 2, 5, or 10 g of added αCD. Postprandial glucose and insulin were assessed.
- Diamantis, Bär (2002) (Diamantis 2002b; a), subsequently published as (Bär 2020): 12 healthy male adults age 23–24 consumed white bread (50 g starch) with 0 or 10 g αCD dissolved in 250 mL drinking water. Postprandial glucose and insulin were measured.

- Gentilcore (2011): 10 healthy older subjects age 68–78 yr consumed 100 g sucrose with 0 or 10 g aCD dissolved in water. Postprandial glucose and insulin were measured.

The FDA included two more recent studies, although the meals, in particular in the former study, also contained substantial amounts of fat and protein:

- Fletcher (2013) (Fletcher 2013), a dissertation published subsequently as Jarosz et al. (2013) (Jarosz 2013): 34 healthy adults age 18–65 yr consumed a commercially prepared egg sausage biscuit sandwich (32 g carbohydrates, 26 g fat, 20 g protein) with containing 0 or 2 g of αCD (2 pills). Post-prandial glucose and triglycerides were measured.
- Sugahara (2016) (Sugahara 2016): 10 adults age 22.9±1.8 consumed a beef curry and rice meal (86 g carbohydrate, 13.5 g fat, 11 g protein) with 0 or 5 g αCD. Post-prandial glucose, triglycerides, and insulin were measured.

This meta-analysis also contains the results from two studies reviewed by neither of the agencies:

- Lytle (2018) (Lytle 2018): 8 healthy adults age 23–54 yr consumed 2 g αCD with a liquid meal breakfast comprising 60% (37–54 g) carbs, 27.5% fat, and 14.5% protein. While the primary outcome was fat, plasma glucose was also measured.
- Binou (2022) (Binou 2022a; b), NCT04725955: 10 healthy adults age 18–41 (28.2±6.8) consumed white wheat bread (50 g carbohydrates, 2-4 g fat, 10–12 g protein) with 0 or 5 g of αCD. Postprandial glucose and insulin were measured.

RESULTS

Data Extraction

Table 1 shows the numerical results extracted from the seven studies included in the review.

Table 1: Summary Data

Agency	**Publications**	Subjects	Age [yr]	Ingredients	Source	aCD [g]	glucose	insulin	TG
EFSA, FDA	Buckley et al. (2006) (Buckley 2006)	10 healthy adults	24 ± 4	50 g starch	white rice	2, (2) 5, (5) 10 (10)	↓ n.s. ↓ 0.03 ↓ .001	↑ n.s. ↔ n.s. ↓ n.s.	
EFSA, FDA	Diamantis (2002), Bär (2019/2020), Schmid (2005) (Diamantis 2002a; b; Schmid 2004b; Bär 2020)	12 healthy male adults	23–24	50 g starch ~1 mL olive oil	white bread	5 (10)	↓<0.05	↓<0.05	
	Binou (2022) (Binou 2022a; b)	10 healthy adults	18–41	50 g carbs ~3 g fat ~11 g protein	white wheat bread	5 (5)	↓ <0.06	↔ n.s.	
EFSA, FDA	Gentilcore (2011) (Gentilcore 2011)	10 healthy seniors	68–78		**100 g sucrose**	10 (5)	↓ n.s. 1 h: <.05	↓ 0.09 2h: <.001	
FDA	Sugahara (2016) (Sugahara 2016)	10 healthy-adults	23 ± 2	**86 g carbs,** 13.5 g fat 11 g protein	beef curry with rice	5 (3)	↓ <0.37	↓ n.s.	↓ n.s.
FDA	Fletcher (2013), Jarosz (2013) (Fletcher 2013; Jarosz 2013)	34 healthy adults	18–65	**32 g carbs,** **26 g fat,** 20 g protein	McMuffin egg sausage biscuit	2 (3)	↓ n.s.		↓ <0.05
	Lytle (2018) (Lytle 2018)	8 healthy adults	23–54	~45 g carbs, **~21 g fat** ~11 g protein	Ensure Plus liquid meal	2 (2)	↔ n.s.		↔ n.s.

Figure 2 shows the average glucose profile data by diet as presented in the seven clinical trials. Figure 3 shows the serum insulin or triglyceride (TG) profiles as provided in the publications



Figure 2: Data Extraction Summary: Effects of different doses of αCD on blood glucose profiles. In all studies, each of >8 patients was administered all doses (cross-over). Figures have been scaled to have similar scales. Two Figures (Gentilcore 2011; Lytle 2018) has been cropped at 180 min. Legend: ***: $P < .001$; *: $P < .05$; °: $P < .37$



Figure 3**: Data Extraction Summary: Effects of different doses of αCD on serum insulin and triglycerides (TG).** See Figure 2 for legend.

Data Review

One of the most striking observations are the glucose curves in the two studies with the highest content of dietary fat and protein (Jarosz 2013; Lytle 2018). One study (Jarosz 2013) used a high-fat, rather than a high-carb meal and thus, and blood glucose levels increased by only 10% under control conditions, compared to ~50% in all studies serving a high-carb diet. (Figure 1D (Fletcher 2013, Figure 2) of the data extraction summary plot has been rescaled to reflect that aspect.) The other study (Lytle 2018) also served a high-fat liquid meal and, consequently, the graph is very similar. If a diet does not increase blood glucose, however, the addition of αCD cannot reduce an increase significantly, especially not at a small sample size. Hence, these studies will not be further considered for the meta-analysis.

Since the earliest study (Buckley 2006), the use of SEM bars shown in the graphs point to another, potentially common problem in this field: the data collected under different conditions seem to have been analyzed by methods that ignore the within-subject correlations (IWSC), which is a key element in the analysis of a cross-over design. This IWSC flaw seems to have contributed to several of the seemingly "non-significant" results. The text in another study (Sugahara 2016), for instance, reads "the cumulative IAUC … was smaller in the αCD group … than in the control group". Hence, the results are described as if the data were coming from different "groups", which would be consistent with the IWSC flaw having diminished significance. In the latter study, the Fig. 3 caption notes that "Tukey's test" was used to reduce the significance inappropriately even further between the "groups" for the 0–180 min cumulative IAUC.

Meta Analysis

Among the studies with high levels of carbohydrates (bread and rice), the earliest study (Buckley 2006) (Figure 1A) noted "a dose-dependent inhibition of the post-prandial glycaemic response to a standard carbohydrate meal following incorporation of [αCD]. The mean iAUC for glucose was negatively related to the dose of α-CD ($r^2 = 0.97$, $P = 0.02$), with the iAUC being significantly lower than the control dose (0 g αCD) for the 5- ($P = 0.03$) and 10-gram ($P = 0.001$) doses".

The comparisons based on the four subsequent studies (Gentilcore 2011; Sugahara 2016; Bär 2020; Binou 2022a; b), excluding the two studies serving high-fat meals (Jarosz 2013; Lytle 2018), are consistent with the dose-response relationship initially observed (Buckley 2006):

2 g/ 50 g: The low dose used in the initial study (Buckley 2006) was not significant.
No evidence for efficacy (Buckley 2006)**.**

3 g/ 50 g: One study (Sugahara 2016) served beef curry containing fat with 86 g carbs per meal, so the effective "5 g" dose was only 2.9 g per 50 g of starch. Moreover, the Fig. 3 bars being obviously, but not "significantly" different strongly suggests at least one of the Tukey or IWSC flaws .
Efficacy on glucose unclear because of statistical issues (Sugahara 2016)**.**

In one study (Jarosz 2013), where subjects were fed a high-fat (26 g) McMuffin egg sausage biscuit, 2 g αCD reduced **trigycerides** ($P < 0.05$).

5 g/ 50 g: In the initial (Buckley 2006) and a second study (Binou 2022a; b), 5 g were significant (at $P = 0.03$ and $P = 0.06$, respectively, combined $\boldsymbol{P = 0.013}$ (Fisher 1948), well below the FCPT cut-off of 0.0175).

One of the "10 g" studies (actually: 5 g per 50 g sucrose) without a significant result is excluded because the participants were much older (68–76 yr) and consumed a sucrose drink (Gentilcore 2011), rather than a high-carb meal. Still, the presence of at least one significant difference between "groups" suggests that the results increase the

significance from the other two studies.
Significant efficacy for glucose from at least two studies (Buckley 2006; Binou 2022a; b).

The reduction of **insulin** levels in one study (Gentilcore 2011) was not significant ($P = 0.09$).

10 g/ 50 g: The 10 g dose was significant in the initial (Buckley 2006) and in a second study (Bär 2020) ($P < 0.001$ and $P < 0.05$, respectively, combined $\boldsymbol{P < 0.00055}$) (Fisher 1948).
Highly significant efficacy on glucose from two studies (Buckley 2006; Bär 2020).

In one study (Bär 2020), the reduction in **insulin** was also significant ($P < 0.05$).

In summary, all comparisons, even at the 2 g dose, showed lower glucose profiles with αCD and only one comparison (at the 2 g dose) (Gentilcore 2011) showed higher insulin levels with αCD. Hence, the efficacy of αCD when added to a high-carb meal (rice or bread) among young adults is dose-dependent (EFSA Panel on Dietary Products 2012); doses from **5 g/50 g** are proven effective, as concluded by the EFSA in 2012. The αCD's mechanism of action seems not to involve an increase of insulin production.

DISCUSSION

This meta-analysis addresses one of the hypothetical benefits of αCD: the reduction of post-prandial glycemic responses, where EFSA (EFSA Panel on Dietary Products 2012) and FDA (Kavanaugh 2022) have come to different conclusions, even though they agree on the interpretation of the three studies available to the EFSA in 2012:

- 50 g starch in white rice, 2/5/10 g αCD, young adults (Buckley 2006): "a dose-dependent effect" (EFSA Panel on Dietary Products 2012), with no effect at 2 g, but "significant effects of 5 g and 10 g" (Kavanaugh 2022).
- 50 g starch in white bread, 10 g αCD, young adults (Bär 2020): a (significant) effect (EFSA Panel on Dietary Products 2012; Kavanaugh 2022).
- 100 g sucrose drink, 10 g αCD, seniors (Gentilcore 2011): no effect (EFSA Panel on Dietary Products 2012; Kavanaugh 2022).

EFSA: "The Panel considers that the following wording reflects the scientific evidence: "Consumption of alpha-cyclodextrin contributes to the reduction of the blood glucose rise after starch-containing meals" and "in order to obtain the claimed effect, at least 5 g of alpha-cyclodextrin per 50 g of starch should be consumed" (EFSA Panel on Dietary Products 2012).

Two additional studies had been published at the time of the FDA's review (see Materials) (Kavanaugh 2022).

- High-fat meal with 32 g starch, 2 g αCD, adults (Jarosz 2013): no significant difference (Kavanaugh 2022). This study was excluded from the meta-analysis, because of the diet's low carbohydrate content. After the high fat meal, however, αCD reduced TG.
- Beef curry/rice meal, 86 g starch, 5 g αCD, adults (Sugahara 2016), (2.9 g per 50 g of starch) no statistical difference (Kavanaugh 2022). Aside from a low dose of αCD, this study raises substantial issues regarding the validity of the statistical analysis.

FDA: "There is inconsistent evidence … which weakens our confidence … " (Kavanaugh 2022).

Another informative study has been published since:

- 50 g starch in white bread, 5 g αCD,(Binou 2022a; b) $P = 0.06$ (< 0.37). Despite being "not significant" on its own, this study clearly adds further evidence for the dose of 5 g αCD, when added to a high carbohydrate meal, being effective.

From the Results, there are several aspects in the published evidence to resolve at least some of the above inconsistencies.

- A "non-significant" result should not be interpreted as evidence against an effect. ("Lack of proof of an effect is not proof of lack of an effect".) In particular, having one of several studies not reaching the conventional level of significance ($P < 0.05$) does not, in itself, create an inconsistency. With the FCPT (Fisher 1948), adding a study with $P < 0.37$ (Sugahara 2016; Binou 2022a; b) typically suffices to strengthen the overall significance.(Elston 1991)
- Cross-over studies often have more power than two-group comparisons because data coming from the same person tend to be correlated. At least one of the studies (Sugahara 2016), however, apparently analyzed the data without accounting for that correlation, which may have contributed to the "non-significant" statistical results despite clear evidence for an effect from the Figures included with the study. Luckily, the *P*-values, in that study, were still within the range that contributes to the overall significance as calculated by the FCPT.
- One of the recent study (Jarosz 2013) with inconsistent results assessed the effect of αCD when added to a high-fat (rather than high-carb) meal, and, consequently, blood glucose levels did not increase to levels comparable to high-carb meals. Instead, it triglyceride (TG) levels increased, and αCD exerted its beneficial effect by reducing the increase in serum TGs.

The last point relates to another important issue. With high-fat meals, αCD may have other benefits. In the study with the low-carb/high-fat meal (Jarosz 2013), excluded from this meta-analysis for that reason, "consumption of α-CD with a fat-containing meal was associated with a significant reduction in post-prandial [triglyceride] responses" (Jarosz 2013). This significant result was trend was supported by the potentially "nonsignificant trend" in the study with a fat-containing meal (Sugahara 2016).

Hence, the overall benefit of αCD is not restricted to reducing the post-prandial glucose response seen after carb-rich meals. With fat-rich meals (Jarosz 2013), it is blood lipids (incl. TG) that increases and αCD reduces the TG response, instead. In fact, much of the effect of αCD helping obese people to lose weight may be related to αCD reducing lipid, rather than glucose response, which has been demonstrated in several clinical trials:

- Grunberger (2007) / Jen (2013), age >30 yr, 57.5±9. In "obese people with type 2 diabetes … αCD reduced body weight," although this was "only significant after adjusting for energy intake"
- Comerford (2011), age: 41±13.6 yr "In overweight people, … αCD "significantly decreases body weight and LDL"
- Amar (2016) age: 34±12.4. In healthy subjects, αCD reduced Small-LDL by 10% ($P < 0.045$) and insulin resistance by 11% ($P < 0.04$)

Finally, it was noted that there was no clear relationship between postprandial insulin and postprandial glucose. A lack of such relationship, however, can, in fact, be an advantage because it shows that αCD does not lower glucose by increasing insulin production and, thus, have the desirable effect on blood glucose even in people whose insulin production is limited.

Weaknesses of this meta-analysis include the lack of subject-level data and often even of exact *P*-values. Another shortcoming is that the majority of studies were conducted in young adults, while the people who could potentially benefit the most are seniors. More studies in older populations are urgently needed.

CONCLUSIONS

This meta-analysis is based on five published clinical trials on the efficacy of αCD to reduce glucose excursions after a high-carb meal containing ~50 g starch from white bread or rice in subjects aged 18–41 years. There is no indication that this effect requires an increase in insulin production. Two additional publications had the majority of calories came from fat. Hence, these two studies were excluded from the meta-analysis. There were strong indications that the published *P*-values suffered from loss of power due to errors in the statistical methodology, including the cross-over design not being reflected in the statistical method used. Still, a formal meta-analysis using Fisher's combined probability test confirmed the EMA's 2012 health claim that, when taken with a high-carb meal containing ~50 g of starch, 5–10 g of the dietary fiber αCD reduce post-prandial glucose excursions.

ABOUT THE AUTHOR

Dr. Wittkowski received his PhD in computer science from the University of Stuttgart and his ScD (Habilitation) in Medical Biometry from the Eberhard-Karls-University Tübingen, both Germany. After working for 10 years (1988–99), on the Epidemiology of HIV he headed, for 20 years, the Department of Biostatistics, Epidemiology, and Research Design at The Rockefeller University Hospital, New York.

CONFLICT OF INTEREST

Author Knut M. Wittkowski is currently the CEO of ASDERA LLC, a company discovering novel pharmacological and nutritional interventions against complex (incl. cardiovascular) diseases from data of genome-wide association studies. The discussion of statistical aspects in the meta-analysis / systematic review in this publication was not affected by any commercial or financial relationships that could be construed as a potential conflict of interest.

REFERENCES

Bär A, Diamantis I, et al. (2020). Alpha-Cyclodextrin Attenuates the Glycemic and Insulinemic Impact of White Bread in Healthy Male Volunteers. *Foods (Basel, Switzerland)* **9**(1).

Bessell E, Fuller NR, et al. (2020). Effects of α-Cyclodextrin on Cholesterol Control and Hydrolyzed Ginseng Extract on Glycemic Control in People With Prediabetes: A Randomized Clinical Trial. *JAMA Netw Open* **3**(11): e2023491.

Binou P, Stergiou A, et al. (2022a). Correction to: Positive postprandial glycaemic and appetite-related effects of wheat breads enriched with either α-cyclodextrin or hydroxytyrosol/α-cyclodextrin inclusion complex. *Eur J Nutr*.

Binou P, Stergiou A, et al. (2022b). Positive postprandial glycaemic and appetite-related effects of wheat breads enriched with either α-cyclodextrin or hydroxytyrosol/α-cyclodextrin inclusion complex. *Eur J Nutr*.

Buckley JD, Thorp AA, et al. (2006). Dose-dependent inhibition of the post-prandial glycaemic response to a standard carbohydrate meal following incorporation of alpha-cyclodextrin. *Annals of Nutrition and Metabolism* **50**(2): 108-14.

Diamantis IB, A (2002a). Effect of alpha-cyclodextrin on the glycemic index (GI) and insulinemic index (II) of starch in healthy human volunteers. *Unpublished study report*.

Diamantis IB, A (2002b). Effect of alpha-cyclodextrin on the glycemic index (GI) and insulinemic index (II) of starch in human volunteers. *Unpublished study protocol*.

EFSA Panel on Dietary Products, Nutrition and Allergies (NDA), (2012). Scientific Opinion on the substantiation of health claims related to alpha cyclodextrin and reduction of post prandial glycaemic responses (ID 2926, further assessment) pursuant to Article 13(1) of Regulation (EC) No 1924/2006. *EFSA J* **10**(6): 2713.

Elston RC (1991). On Fisher's Method of Combining p-Values. *Biometrical Journal* **33**(3): 339-45.

Fisher RA (1948). Combining independent tests of significance. *The American Statistician* **2**(5): 30.

Fletcher EN (2013). The effect of alpha-cyclodextrin on acute blood lipid and glycemic responses to a fat containing meal. *Nutrition and Food Scienced*, Wayne State University. **M.S.**

Gentilcore D, Vanis L, et al. (2011). The oligosaccharide alpha-cyclodextrin has modest effects to slow gastric emptying and modify the glycaemic response to sucrose in healthy older adults. *The British journal of nutrition* **106**(4): 583-7.

Jarosz PA, Fletcher E, et al. (2013). The effect of alpha-cyclodextrin on postprandial lipid and glycemic responses to a fat-containing meal. *Metabolism* **62**(10): 1443-7.

Jen C, Grunberger G, et al. (2013). On the binding ratio of α-cyclodextrin to dietary fat in humans. *NutrDietSuppl* **5**: 9-15.

Kavanaugh CFC (2022). Final Response Letter from FDA CFSAN to Hyman Phelps and McNamara PC. FDA-2019-P-6045-0021.

Littell RC, Folks JL (1973). Asymptotic Optimality of Fisher's Method of Combining Independent Tests II. *J Am Statist Assoc* **68**(341): 193-4.

Lytle KA, Harteneck DA, et al. (2018). The Soluble Fiber alpha-Cyclodextrin Does Not Increase the Fecal Losses of Dietary Fat in Adults-A Double-Blind, Randomized, Placebo-Controlled, Crossover Trial. *J Nutr* **148**(9): 1421-5.

Plank David W, Delvecchio Anthony J (2006). Reduced trans fat product. US, GEN MILLS INC.

Schmid G, Reuscher H, et al. (2004a). Method for reducing the glycemic index of food. US, WACKER CHEMIE GMBH.

Schmid G, Reuscher H, et al. (2004b). Method For Reducing The Glycemic Index Of Food. *EP 1447013 A1*. EP, WACKER CHEMIE GMBH.

Soldavini CM, Piuri G, et al. (2022). Maternal AA/EPA Ratio and Triglycerides as Potential Biomarkers of Patients at Major Risk for Pharmacological Therapy in Gestational Diabetes. *Nutrients* **14**(12).

Sugahara M, Inoue Y, et al. (2016). Effect of cyclodextrin on postprandial blood glucose and triglycerides. *Int J Pharm* **6**(3): 13-9.